Onconova Therapeutics Company Profile (NASDAQ:ONTX)

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONTX
  • CUSIP: N/A
  • Web: www.onconova.com
Capitalization:
  • Market Cap: $24.13 million
  • Outstanding Shares: 9,851,000
Average Prices:
  • 50 Day Moving Avg: $1.92
  • 200 Day Moving Avg: $2.04
  • 52 Week Range: $1.46 - $3.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.36 million
  • Price / Sales: 10.23
  • Book Value: ($0.04) per share
  • Price / Book: -61.25
Profitability:
  • EBITDA: ($22,150,000.00)
  • Net Margins: -762.13%
  • Return on Equity: -558.97%
  • Return on Assets: -85.62%
Debt:
  • Current Ratio: 1.62%
  • Quick Ratio: 1.62%
Misc:
  • Average Volume: 151,037 shs.
  • Beta: 0.11
  • Short Ratio: 15.94
 

Frequently Asked Questions for Onconova Therapeutics (NASDAQ:ONTX)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its earnings results on Monday, August, 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.43. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. View Onconova Therapeutics' Earnings History.

When will Onconova Therapeutics make its next earnings announcement?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Onconova Therapeutics.

Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2017?

4 analysts have issued 12 month price objectives for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Onconova Therapeutics' share price to reach $7.33 in the next year. View Analyst Ratings for Onconova Therapeutics.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:

  • Michael M. B Hoffman, Chairman of the Board
  • Ramesh Kumar Ph.D., President, Chief Executive Officer, Director
  • Mark Guerin, Chief Financial Officer
  • Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer
  • Manoj Maniar Ph.D., Senior Vice President - Product Development
  • Henry S. Bienen Ph.D., Director
  • Jerome E. Groopman M.D., Director
  • Viren Mehta Ph.D., Director
  • E. Premkumar Reddy Ph.D., Director
  • Jack E. Stover CPA, Director

How do I buy Onconova Therapeutics stock?

Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of Onconova Therapeutics stock can currently be purchased for approximately $2.45.


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  166
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Onconova Therapeutics (NASDAQ:ONTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33 (199.32% upside)
Consensus Price Target History for Onconova Therapeutics (NASDAQ:ONTX)
Price Target History for Onconova Therapeutics (NASDAQ:ONTX)
Analysts' Ratings History for Onconova Therapeutics (NASDAQ:ONTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017HC WainwrightInitiated CoverageBuy -> Buy$6.00N/AView Rating Details
8/15/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00LowView Rating Details
12/9/2015Piper Jaffray CompaniesReiterated RatingOverweight$60.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Onconova Therapeutics (NASDAQ:ONTX)
Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Earnings History by Quarter for Onconova Therapeutics (NASDAQ ONTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.73)N/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Onconova Therapeutics (NASDAQ:ONTX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.72)($0.72)($0.72)
Q3 20171($0.73)($0.73)($0.73)
Q4 20171($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Onconova Therapeutics (NASDAQ:ONTX)
Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 26.83%
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Insider Trades by Quarter for Onconova Therapeutics (NASDAQ:ONTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.90View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.60View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.00View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.00View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.00View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Onconova Therapeutics (NASDAQ:ONTX)
Latest Headlines for Onconova Therapeutics (NASDAQ:ONTX)
Source:
Loading headlines, please wait.

Social

Chart

Onconova Therapeutics (ONTX) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.